Emerging Data and Treatment Trends in Paroxysmal Nocturnal Hemoglobinuria After EHA 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, on updates in paroxysmal nocturnal hemoglobinuria.

EP. 1: Reviewing Current Standards in Paroxysmal Nocturnal Hemoglobinuria

June 24th 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, on the current management of paroxysmal nocturnal hemoglobinuria.

EP. 2: Role of C5 Inhibitors in the Management of Paroxysmal Nocturnal Hemoglobinuria

July 2nd 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, on the current management of paroxysmal nocturnal hemoglobinuria.

EP. 3: Implications of the FDA Approval of Iptacopan for PNH

July 9th 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, on the implications of the FDA approval of Iptacopan for PNH.

EP. 4: Data for Iptacopan in PNH After Switching Anti-C5 Therapy: The APPULSE-PNH Trial

July 16th 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, on data for iptacopan in PNH after switching anti-C5 therapy.

EP. 5: Factors for Selecting Iptacopan in C5 Inhibitor–Naive and –Exposed PNH

July 23rd 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, detail factors for selecting iptacopan in C5 inhibitor–naive and –exposed PNH.

EP. 6: Implications of APPULSE-PNH Data for Iptacopan in PNH

July 30th 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, discuss implications of data from the APPULSE-PNH trial of iptacopan.

EP. 7: Addressing Further Unmet Needs in PNH

July 30th 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, discuss unmet needs to address in the management of PNH.

x